NEW YORK (GenomeWeb News) - Invitrogen said today it will buy primary cell provider CellzDirect for around $57 million in cash in an effort to expand its cellular analysis business.
 
CellzDirect’s human hepatocyte-based cell products and services are used in drug testing, particularly for predicting the effect of compounds on enzymatic metabolism in the liver.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.